Clinical Trial Update: Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 endometrial safety study of a 300 mcg/day transdermal testosterone in naturally postmenopausal women with hypoactive sexual desire disorder has complete…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypoactive Sexual Desire Disorder

Drugs mentioned

• Transdermal Testosterone 300 mcg/day (testosterone)

Snippet

Sponsor: Warner Chilcott | Conditions: Hypoactive Sexual Desire Disorder | Phase 3 | Status: COMPLETED | Results posted: 2011-12-15